Sentences with phrase «diagnostic cancer testing»

If your primary veterinarian suspects cancer, a referral to VSS may include advanced diagnostic cancer testing — including ultrasound, CT scans, and biopsy procedures — to identify the type, location, and behavior of a tumor.

Not exact matches

A big part of what's driving Opdivo's success is an early decision by BMS to chase a much wider share of the cancer patient population — a decision that has meant that doctors don't have to administer a time - consuming diagnostic test to check if patients have a protein called PD - L1 before prescribing Opdivo in certain cancers.

Their ideas ran the gamut, including an all - natural sports products manufacturer, IT solutions to enhance hotel guest services, a medical diagnostic kit to test women's tears for proteins that indicate breast cancer, mobile phone apps to streamline India's vast street markets, and more.

Mammograms may be one imaging modality for breast cancer screening but there are other diagnostic tests that can be done, including ultrasound and MRIs.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward - looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and adequately reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1cancer screening and diagnostic products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 1cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10 - K and our subsequently filed Quarterly Reports on Form 10 - Q.

Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

April 10 Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

The partnership will seek approval for a version of the Illumina's test, TruSight Tumor 170, as a companion diagnostic for Loxo's larotrectinib and another one of Loxo's experimental cancer drugs, across tumor types.

Prior to joining Oberon, David was Chief Financial Officer and Treasurer at VolitionRx (NYSE MKT: VNRX), a multi-national medical diagnostics company developing simple blood - based tests to accurately diagnose a range of cancers.

Repligen has long been a global leader in Protein A ligands, which are formulated into resins and used to purify monoclonal antibodies, which are used for diagnostic tests and theraputic treatments for cancer and inflammation.

Undergoing treatment now: Nursing is safe during diagnostic tests for cancer such as a mammogram (although it may be harder to read during lactation), X-ray, CAT scan, MRI, ultrasound, and biopsy.

These include radioactive drugs used for some diagnostic tests like Gallium - 69, Iodine - 125, Iodine - 131, or Technetium - 99m, antimetabolites, and a few cancer chemotherapy agents.

Our hearing testing offerings include diagnostic audiology services, intra-operative testing, auditory brainstem response (ABR) testing, inner ear evaluations, specialized screening for newborns, infants and toddlers and patients with cancer.

Breastfeeding can continue during most diagnostic testing for cancer.

In most cases diagnostic tests for breast cancer, including a mammogram, MRI, X-ray, CAT scan, PET scan or CT scan, do not affect the safety or quantity of breast milk.

Although very rare in a breastfeeding mother, it is important to rule out any possibility of breast cancer, and most diagnostic tests are compatible with breastfeeding.

May, who has announced that funding for brain cancer research would be doubled and better diagnostic tests rolled out to all NHS hospitals in tribute, said the former Labour cabinet minister's dignity and courage were «as humbling as they were inspirational», adding: «Even at what must have been some of her most difficult moments, her compassion for others shone through.»

Professor Anderson believes that if the LGS proves to be a useful cancer diagnostic test, it would be a highly valuable addition to the more traditional investigative procedures for detecting cancer.

The FDA approved PSA screening in 1986 as a diagnostic test to detect prostate cancer, and it has been controversial from the beginning.

A major focus of my research is on developing new technologies, based on hypothesis - driven, targeted mass spectrometry, for relieving this bottleneck to testing potential new blood - based diagnostics for detection of cancer.

We extended our molecular diagnostics to test for a genetic rearrangement that had been reported in lymphoma and lung cancer, but never in mesothelioma.

Medical devices range from the simple, such as Band - Aids, to the high - tech, such as imaging machines and the BRCA1 and BRCA2 molecular diagnostic tests for breast cancer (see sidebar).

«Based on this study, we intend to customise a diagnostic test for each colorectal cancer individual.

«It's very surprising that the nematodes exhibited such a strong binary response to «cancer» versus «no cancer» urine,» says Michael Phillips at Menssana Research, a New Jersey - based company developing diagnostic tests based on people's breath.

This finding is significant in helping to develop personalised diagnostic tests for patients with colorectal cancer based on the genetic changes present in each individual's colon tumour.

«Thus, there is still a need to develop new diagnostic technologies with higher accuracy, deeper penetration, larger scanning regions, and lower cost for the routine tests of cervical cancer,» Xiao said.

The researchers, who have since spun off MiRXES, a biotechnology startup, are now working with the Singapore Gastric Cancer Consortium and the A * STAR Diagnostic Development Hub to develop a test that detects gastric cancer before symptoms aCancer Consortium and the A * STAR Diagnostic Development Hub to develop a test that detects gastric cancer before symptoms acancer before symptoms appear.

«Future research into the role and function of vlincRNAs holds promise for both highly targeted diagnostic tests and more precise cancer treatments.

The researchers enrolled 82 people in the study who had been referred for a full diagnostic test after an x-ray suggested the presence of lung cancer.

In terms of diagnostics, it has six tests on the market, based on research in Iceland, that aim to measure risk of diseases such as heart attack and prostate cancer.

If we are able to refine a test to diagnose lung cancer by measuring breath temperature, we will improve the diagnostic process by providing patients with a stress - free and simple test that is also cheaper and less intensive for clinicians.»

One early project was to help Genoptix — a Novartis daughter - company acquired in 2011 and located in Carlsbad, California — to commercialize a diagnostic test for lung cancer patients.

However, when there's a low - to - moderate probability of cancer — anywhere from 5 to 65 percent — providers may debate who should be monitored with serial PET or CT scans and who should undergo potentially complex diagnostic tests.

His ensuing two - decade quest led to the discovery and 1998 approval of the breast cancer drug Herceptin, and to a companion diagnostic test that looks for an overproduction of her2 proteins.

The decision was a defeat for biotech firm Myriad Genetics, which has patent claims on two breast cancer genes, and means that diagnostic labs are now free to test for these genes without fear of a lawsuit.

These patients then face the prospect of a long wait with numerous diagnostic tests and attempts to locate the origin of the cancer before starting any treatment.

The researchers found that of the 614 eligible patients included in the analysis, 27 % had no preoperative diagnostic procedure, 22 % did not have an imaging scan to stage the cancer, and 88 % did not have an invasive staging test.

He suggests that current estimates of cancer risk from low doses of radiation — say, from naturally occurring radon and diagnostic tests — may underestimate the danger by failing to take into account bystander effects.

Australia's Full Federal Court this week began proceedings in an appeal of an earlier decision that upheld the validity of breast cancer diagnostic tests developed by Myriad Genetics — the same tests that were the subject of oral argument before the U.S. high court earlier this week.

Today, his discoveries continue to lead his lab and others around the world in developing genetic tests, diagnostics and therapies for cancer.

The outcomes of interest were also a priori determined by the Panel and included prostate cancer incidence, mortality, quality of life, the diagnostic performance of each of the tests and the harms of testing (premature death and complications from testing and biopsy).

A literature review finds an increased risk of cancer, late - stage cancer, and mortality, with increased waiting time between a positive screening and start of diagnostic testing.

Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.

For example, the discovery of cancer - causing genetic and epigenetic changes in tumors has enabled the development of therapies that target these changes as well as diagnostic tests that identify patients who may benefit from these therapies.

Using examples including hereditary breast cancer, Dr. Lacbawan explores the diagnostic applications of sequencing, comparing when to use next generation cancer gene panels versus gene by gene testing.

deCODE is delivering on the promise of the new genetics.SM Visit us on the web at www.decode.com; on our diagnostics site at www.decodediagnostics.com; for our pioneering personal genome analysis service and new Cardio and Cancer scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at www.decodeme.com; and on our blog at www.decodeyou.com.

Technique enables development of viable diagnostic tests and instruments in fight against cancer Cancer is the second leading cause of death in the U.S., making early, reliable diagnosis and... Reacancer Cancer is the second leading cause of death in the U.S., making early, reliable diagnosis and... ReaCancer is the second leading cause of death in the U.S., making early, reliable diagnosis and... Read more

deCODE is delivering on the promise of the new genetics.SM Visit us on the web at www.decode.com; on our diagnostics site at www.decodediagnostics.com; for our pioneering personal genome analysis service and new focused disease scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, as well as for our new deCODEme Cardio ™ and deCODEme Cancer ™ scans, at www.decodeme.com; and on our blog at www.decodeyou.com.

In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests and technologies for various cancer therapies, helping to realize the promise of precision oncology.

NCI, a component of the National Institutes of Health, established the Nanotechnology Characterization Laboratory to perform pre-clinical efficacy and toxicity testing of nanoparticles intended for cancer therapeutics or diagnostics.